Tamiflu (Oseltamivir) Indications and Dosage
Tamiflu is indicated for treatment of influenza in patients ≥1 year old who have been symptomatic for no more than 2 days, and for prophylaxis of influenza in patients ≥1 year old. 1
Primary Indications
Treatment Indications
- Any child hospitalized with presumed influenza - regardless of symptom duration
- High-risk patients including those with:
- Asthma or chronic respiratory disease
- Diabetes mellitus
- Immunosuppression
- Neurologic disorders
- Cardiac disease
- Age <2 years (particularly <6 months)
- Otherwise healthy patients presenting within 48 hours of symptom onset 2
Prophylaxis Indications
- High-risk patients for whom influenza vaccine is contraindicated
- High-risk patients during the 2 weeks after influenza immunization (before protective antibodies develop)
- Unimmunized family members/healthcare workers with ongoing close exposure to high-risk or young children (<24 months)
- Control of institutional outbreaks in closed settings
- Post-exposure prophylaxis for household contacts (within 48 hours of index case symptom onset)
- Adjunctive prophylaxis for immunocompromised patients who may not respond adequately to vaccine 2
Treatment Dosing (5 Days Duration)
Adults and Adolescents (≥13 years)
75 mg orally twice daily for 5 days 3
Pediatric Patients (≥12 months)
Weight-based dosing:
- ≤15 kg (≤33 lb): 30 mg twice daily
- >15-23 kg (33-51 lb): 45 mg twice daily
- >23-40 kg (51-88 lb): 60 mg twice daily
- >40 kg (>88 lb): 75 mg twice daily 3
Infants (Birth to <12 months)
Age 9-11 months: 3.5 mg/kg/dose twice daily 3
Term infants 0-8 months: 3 mg/kg/dose twice daily 3
Preterm infants (based on postmenstrual age):
- <38 weeks postmenstrual age: 1.0 mg/kg/dose twice daily
- 38-40 weeks postmenstrual age: 1.5 mg/kg/dose twice daily
- >40 weeks postmenstrual age: 3.0 mg/kg/dose twice daily 3
Critical caveat: Infants <3 months have limited safety data. However, given the high vulnerability of this age group and lack of alternatives, treatment is appropriate when influenza is suspected or confirmed. 3, 4
Prophylaxis Dosing (10 Days Duration)
Adults and Adolescents (≥13 years)
75 mg orally once daily for 10 days (or up to 6 weeks during community outbreak) 3
Pediatric Patients (≥12 months)
Weight-based dosing (once daily):
- ≤15 kg: 30 mg once daily
- >15-23 kg: 45 mg once daily
- >23-40 kg: 60 mg once daily
- >40 kg: 75 mg once daily 3
Infants (3-11 months)
3.5 mg/kg/dose once daily (for 9-11 months) or 3 mg/kg/dose once daily (for 3-8 months) 3
Infants <3 months: Prophylaxis is not recommended unless the situation is judged critical, due to limited data 2, 3
Renal Impairment Dosing
Creatinine clearance 10-30 mL/min:
Treatment: 75 mg once daily for 5 days
Prophylaxis: 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 total doses) 3
Administration Details
Formulations
- Capsules: 30 mg, 45 mg, 75 mg
- Oral suspension: Powder reconstituted to 6 mg/mL final concentration 3, 1
Key Administration Points
- Can be taken without regard to meals, though administration with food may improve GI tolerability 3
- If commercial suspension unavailable, capsules can be opened and mixed with sweetened liquid, or pharmacies can compound suspension (6 mg/mL concentration) 3
- Initiate treatment as early as possible - efficacy greatest when started within 48 hours of symptom onset, though hospitalized patients should receive treatment regardless of symptom duration 2, 3
Critical Clinical Considerations
Timing is Everything
The most important factor determining oseltamivir efficacy is early initiation. Treatment started within 36 hours of symptom onset provides maximum benefit - reducing illness duration by up to 1.5 days and severity by up to 38% 5. However, do not withhold treatment from hospitalized patients even if presenting beyond 48 hours, as they represent a high-risk population where potential benefits outweigh risks 2.
Not a Vaccine Substitute
Oseltamivir prophylaxis does not replace annual influenza vaccination and should not be used as such 1. The drug provides temporary protection only during the administration period.
Resistance Monitoring
Local surveillance data should guide empiric treatment decisions. During recent seasons, most influenza strains have been susceptible to oseltamivir, but resistance patterns can change. Amantadine and rimantadine should not be used due to high resistance rates 6, 2.
Drug Interactions
Do not administer live attenuated influenza vaccine (LAIV) until 48 hours after stopping oseltamivir. Conversely, do not give oseltamivir until 2 weeks after LAIV administration, unless medically indicated, as the antiviral may interfere with vaccine virus replication 1.
Special Populations
Immunocompromised pediatric patients may benefit from extended treatment duration (10 days twice daily dosing) rather than the standard 5 days, particularly to prevent viral rebound 7. Pregnant women can receive oseltamivir at any time during pregnancy to protect themselves and provide transplacental antibody transfer to the fetus 3.